XML 30 R18.htm IDEA: XBRL DOCUMENT
v3.22.1

Stock-Based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2021
Stock-Based Compensation [Abstract] |
Stock-Based Compensation | 11. Stock-Based Compensation Stock based compensation has been reported within expense line items on the consolidated statement of operations for the years ended 2020 and 2021 as shown in the following table (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Year Ended
​ |  | December 31,
​ | ​ | 2020 |  | 2021
General and administrative | ​ |  | 278 | ​ | $ | 819
Research and development | ​ | ​ | 152 | ​ | ​ | 338
Stock-based compensation costs before income taxes | ​ | $ | 430 | ​ | $ | 1,157
​ 2018 Plan ​ In May 2018, the Company’s stockholders approved the 2018 Equity Incentive Plan (the “2018 Plan”), under which Cyclacel may make equity incentive grants to its officers, employees, directors and consultants. The 2018 Plan allows for various types of award grants, including stock options and restricted stock units. As of December 31, 2021, the Company has reserved 522,294 shares of the Company’s common stock under the 2018 Plan. Stock option awards granted under the Company’s equity incentive plans have a maximum life of 10 years and generally vest over a one to four-year period from the date of grant. ​ 2020 Inducement Equity Incentive Plan ​ In October 2020, the Inducement Equity Incentive Plan (the “Inducement Plan”), became effective. Under this Plan, Cyclacel may make equity incentive grants to new senior level Employees (persons to whom the Company may issue securities without stockholder approval). The Inducement Plan allows for the issuance of up to 200,000 shares of the Company’s common stock (or the equivalent of such number). As of December 31, 2021, 120,000 shares under the Inducement Plan have been issued, leaving a remaining reserve of 80,000 shares. ​ Option Grants ​ There were 511,800 options granted during the year ended December 31, 2020. Of these awards, 391,800 were issued under the 2018 Plan and the remaining 120,000 shares were issued under the Inducement Plan. ​ There were 552,153 options granted during the year ended December 31, 2021, all issued under the 2018 Plan. ​ The weighted average grant-date fair values of options granted during the years ended December 31, 2020 and 2021 were $3.47 and $3.36, respectively. ​ As of December 31, 2021, the total remaining unrecognized compensation cost related to the unvested stock options with service conditions amounted to approximately $2.5 million, which will be amortized over the weighted-average remaining requisite service period of 2.37 years. ​ During the years ended December 31, 2020 and 2021, the Company did not settle any equity instruments with cash. ​ There were no stock option exercises during the year ended 2020. There were 6,600 stock option exercises during the year ended 2021. No income tax benefits were recorded for the years ended December 31, 2020 and 2021. The Company does not expect to be able to benefit from the deduction for stock option exercises that may occur because the Company has tax loss carryforwards from prior periods that would be expected to offset any potential taxable income. ​ Outstanding Options A summary of the share option activity and related information is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | ​ | ​ |  | Weighted |  | ​ | ​
​ |  | ​ |  | Weighted |  | Average |  | ​ | ​
​ |  | Number of |  | Average |  | Remaining |  | Aggregate
​ | ​ | Options |  | Exercise |  | Contractual | ​ | Intrinsic
​ | ​ | Outstanding | ​ | Price Per Share |  | Term (Years) | ​ | Value ($000)
Options outstanding at December 31, 2019 |  | 100,279 | ​ | $ | 54.40 |  | 8.62 | ​ | $ | 4
Granted |  | 511,800 | ​ | $ | 4.17 |  | — | ​ |  | —
Exercised |  | — | ​ | ​ | — |  | — | ​ |  | —
Cancelled/forfeited |  | (9,396) | ​ | $ | 101.05 |  | — | ​ |  | —
Options outstanding at December 31, 2020 |  | 602,683 | ​ | $ | 11.01 |  | 9.39 | ​ | $ | 4
Granted |  | 552,153 | ​ | $ | 4.26 |  | — | ​ |  | —
Exercised |  | (6,600) | ​ | ​ | 3.35 |  | — | ​ |  | —
Cancelled/forfeited |  | (48,879) | ​ | $ | 14.18 |  | — | ​ |  | —
Options outstanding at December 31, 2021 |  | 1,099,357 | ​ | $ | 7.53 |  | 8.99 | ​ | $ | 189
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Unvested at December 31, 2021 |  | 801,924 | ​ | $ | 4.14 |  | 9.49 | ​ | $ | 180
Vested and exercisable at December 31, 2021 |  | 297,433 | ​ | $ | 16.66 |  | 7.62 | ​ | $ | 9
​ The fair value of the stock options granted is calculated using the Black-Scholes option-pricing model as prescribed by ASC 718 using the following assumptions:
​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​
​ | ​ | Year ended | ​ | Year ended
​ |  | December 31, 2020 |  | December 31, 2021
Expected term (years) |  | 5–6 |  | 5–6
Risk free interest rate |  | 0.410% – 0.570% | ​ | 0.420% – 1.290%
Volatility |  | 96 – 115% | ​ | 95 – 102%
Expected dividend yield over expected term |  | 0.00% | ​ | 0.00%
Resulting weighted average grant date fair value |  | $3.47 | ​ | $3.36
​ Restricted Stock Units The Company issued 14,000 restricted stock units to employees during the year ended December 31, 2019. The Company issued 3,938 additional restricted stock units to employees during the year ended December 31, 2020, of which 1,491 units have been forfeited. The vesting of the remaining 16,524 outstanding restricted stock units was dependent upon the fulfillment of certain clinical conditions. The Company determined that the clinical conditions would not be satisfied as of December 31, 2021 and, as a result, these restricted stock units were cancelled as of December 31, 2021. ​ The Company issued an additional 18,992 restricted stock units to non-executive directors of the Company during the year ended December 31, 2021. These restricted stock units will vest over a period of one or three years. Each restricted stock unit was valued at $6.69 based on their fair value at the date of grant, which is equivalent to the market price of a share of the Company’s common stock. Summarized information for restricted stock units’ activity for the year ended December 31, 2021 is as follows: ​
​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | Weighted
​ |  | ​ |  | Average
​ | ​ | Restricted |  | Grant Date
​ | ​ | Stock Units | ​ | Value Per Share
Restricted Stock Units outstanding at December 31, 2020 |  | 16,524 | ​ | $ | 11.30
Granted | ​ | 18,992 | ​ | ​ | 6.69
Cancelled/forfeited | ​ | (16,524) | ​ | ​ | 15.20
Restricted Stock Units outstanding at December 31, 2021 | ​ | 18,992 | ​ | $ | 6.69
​ | ​ | ​ | ​ | ​ | ​
Unvested at December 31, 2021 |  | 18,992 | ​ | $ | 6.69
Vested and exercisable at December 31, 2021 |  | — | ​ | $ | —
​

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration